


# CLINICAL TRIAL

CNGA3 - NCT02610582

Research



## Safety and efficacy of a single subretinal injection of rAAV.hCNGA3 in patients with CNGA3-linked achromatopsia investigated in an exploratory, dose-escalation trial

Rare Eye Disease concerned by the trial :  
CNGA3-linked achromatopsia

Status of the trial : completed

Orphan drug recognition : Yes

**Inclusion criteria :** clinical diagnosis of achromatopsia, age  $\geq 18$  years, confirmed mutation in CNGA3, BCVA  $\geq 20/400$ ; first cohort: BCVA  $\leq 20/160$ , area of residual outer nuclear layer thickness in OCT scans of posterior pole, ability to understand and willingness to consent to study protocol.

**Exclusion criteria :** [click here to see detailed criteria](#)



Inclusion opening date : 12/09/2014



Inclusion closing date : 22/09/2016

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**Center for Ophthalmic Research, University Hospital of Tübingen**

Elfriede-Aulhorn-Str. 7  
72076 Tübingen  
Germany

[Contact details](#)



Principal investigator name :

Prof. Dr. Dr. Dominik Fischer




Other investigators :

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

**University Hospital of Tübingen**

Tübingen, Germany



Funder type : Other

[More informations](#)